Abstract We studied the effect of raloxifene (RAL) on arthritis and bone mineral density (BMD) in rats with collagen-induced arthritis (CIA). Seven-month-old female Sprague-Dawley rats were divided into five groups: rats without CIA (CNT), CIA rats that underwent ovariectomy (OVX) and were treated with RAL (CIA ? OVX ? RAL), CIA rats that underwent OVX and were treated with vehicle (CIA ? OVX ? Veh), CIA rats that had sham surgery and were treated with RAL (CIA ? sham ? RAL), and CIA rats that had sham surgery and were treated with vehicle (CIA ? sham ? Veh). RAL was orally administered at 10 mg/kg every day for 3 weeks, beginning 1 week after initial sensitization until death at 4 weeks. Every week until death, we evaluated hind paw thickness and arthritis score. BMD was measured by peripheral quantitative computed tomography at the distal metaphysis and the diaphysis of the femur; we also performed histomorphometry of the proximal tibia and histological evaluation of arthritis. RAL administration suppressed hind paw thickness and arthritis score and prevented decreases in BMD and cortical thickness. In the histomorphometric analysis, bone-resorption parameters were significantly lower in the RAL groups than in the Veh groups. RAL significantly inhibited synovial proliferation in CIA rats. RAL effects on arthritis and bone were apparent regardless of whether an animal had undergone OVX. RAL could suppress arthritis and bone loss in estrogen-replete or -depleted rats. These findings, using an animal model, indicate the potential usefulness of RAL as an effective treatment for premenopausal RA patients as well as postmenopausal ones.
compounds, raloxifene (RAL) is the most clinically successful as an antiosteoporotic agent. RAL reduces the risk of new vertebral fractures by 61% at 1 year [6] and by 55% at 3 years [7, 8] . RAL administration suppresses inflammation in ovariectomized (OVX) animals in models of arthritis [9] [10] [11] ; however, no data are available to elucidate the effects of RAL on arthritis in estrogen-replete animals. Therefore, we investigated the influence of RAL on arthritis as well as bone loss using non-OVX as well as OVX CIA rats.
Materials and Methods

Animals
Seven-month-old female Sprague-Dawley rats (retired breeder animals with a body weight of 310-400 g; Shimizu Laboratory Supply, Kyoto, Japan) were used. This experiment was conducted at the animal study facility of Tottori University School of Medicine, with approval by the Animal Experiment Ethical Committee of Tottori University. Animals were given tap water and solid food (calcium content 1.18 g/100 g, phosphorus content 1.09 g/100 g, vitamin D 3 content 250 IU/100 g) (CE-2; Clea, Tokyo, Japan) ad libitum. Animals were maintained in an animal room, which was illuminated for 12 h daily (7:00-19:00), at a temperature of 24°C. Animals were used in experiments after a 4-week acclimation period.
Animals were divided into the following five groups: (1) injection of only the saline used for collagen sensitization ? only the vehicle used for RAL administration (n = 10, CNT); (2) collagen sensitization ? OVX ? RAL administration (n = 13, CIA ? OVX ? RAL); (3) collagen sensitization ? OVX ? vehicle administration (n = 11, CIA ? OVX ? Veh); (4) collagen sensitization ? sham surgery ? RAL administration (n = 10, CIA ? sham ? RAL); (5) collagen sensitization ? sham surgery ? vehicle administration (n = 12, CIA ? sham ? Veh).
The five experimental groups described above were examined weekly for body weight, arthritis score, and hind paw thickness. Four weeks after initial sensitization, rats were anesthetized by intraperitoneal injection of ketamine hydrochloride (Ketalar; Sankyo, Tokyo, Japan) plus xylazine (Celactal; Bayer, Leverkusen, Germany) (2:1) at 1 mL/kg, blood was collected by cardiac puncture, and the animals were killed. The left knee joint, the right femur, and both feet were resected and fixed in 70% alcohol at 4°C for analysis.
Preparation of the CIA Model
Under intraperitoneal anesthesia with ketamine hydrochloride plus xylazine (2:1) at a dose of 1 mL/kg, 1.0 mL of an emulsion containing 500 lg of bovine type II collagen in 0.3% acetic acid solution (catalog K-41; CosmoBio, Tokyo, Japan) and 500 lg of Freund's incomplete adjuvant (catalog 263910; Difco, Detroit, MI) were injected intracutaneously at three sites on the back of each rat. For additional sensitization, 0.5 mL of the same emulsion was injected intracutaneously at two sites on the posterior aspects of both hip joints 1 week after initial sensitization; OVX or sham surgery was performed at the same time. In the CNT group, physiologic saline was injected intracutaneously, using the same volume and methods applied for the other four groups [12] [13] [14] .
Methods of Drug Administration RAL (LY#139481; Lilly Research Laboratories, Indianapolis, IN) was dissolved in 20% hydroxypropyl-ß-cyclodextrin (catalog 324-84233; Wako Pure Chemical Industries, Osaka, Japan) and administered orally at 10 mg/ kg every day for 3 weeks, beginning 1 week after initial sensitization. The dose is about 10 times higher than the usual dose used for the treatment of osteoporosis in humans; however, this higher dose was used based on previous observations and is considered to be appropriate in experimental animals [10] . We selected this dose in order to investigate the effect of RAL on arthritis during a 4-week observational period. In the groups with vehicle, only the 20% hydroxypropyl-ß-cyclodextrin was administered orally, using the same volume and methods applied for the RAL groups.
Evaluation of Arthritis
Rats were examined for body weight, arthritis score, and hind paw thickness every week until death. Arthritis was evaluated according to the degree of severity and the extent of erythema and edema of the periarticular tissue, scored as 0-3 points [14] , where 0 = normal, 1 = detectable, 2 = moderate, and 3 = severe. The arthritis score was the sum of the scores for both hind legs, toe, hind paw, ankle joint, and knee joint (maximum possible score 24) [14] . Hind paw thickness was evaluated by measuring ankle width from the medial malleolus to the lateral malleolus using a constant-tension caliper [14] . Hind paw thickness was expressed as the mean of both hind legs.
Radiographic Examination
Radiographs of resected right and left feet were obtained with a Multi soft X-ray film shooting apparatus (SOFTEX M-60; Softex, Tokyo, Japan). Destruction of bone and cartilage was classified and scored according to the method described by Engelhardt et al. [15] , which assesses detailed changes in the spongiosa, periosteum, and compact bone around the arthritic joint. Radiographs were evaluated by three observers who were blinded as to the study groups. The radiographic score was the mean of the scores assigned by three observers.
Measurement of BMD and Cortical Bone Thickness
Volumetric BMD (vBMD, expressed in milligrams per centimeter cubed) and cortical bone thickness were measured by peripheral quantitative computed tomography (QCT) (model XCT-960 scanner; Norland-Stratec, Pforzheim, Germany) of the distal metaphysis (2 mm proximal to the growth cartilage) and diaphysis (5 mm proximal to the growth cartilage) of the resected right femur. The scan beam was attached to the distal metaphysis of the right femur perpendicularly to the bone axis; after identifying the metaphysis and diaphysis by scout scanning, the measurement was performed at a voxel size of 0.295 mm and a slice thickness of 1 mm. Parameters of measurement were determined as follows: contmode 2 (for bone contour), peelmode 20 (for trabecular region), contmode 1 (for cortical region), and threshold 0.63 for vBMD of cancellous bone and 0.93 for vBMD of cortical bone [16, 17] . Coefficients of variation (CVs) for this measurement with repositioning were 2.8% for cancellous bone and 3.3% for cortical bone [17] .
Bone Histomorphometry
Bone labeling by intraperitoneal injection of calcein at 10 mg/kg was performed twice: at 6 days and 1 day before death (schedule of 1-4-1-1). The left knee joint (from onethird of the distal femur to one-third of the proximal tibia), resected at death, was fixed in 70% alcohol. The knee joints were then stained with Villanueva bone stain and embedded in methylmethacrylate resin without decalcification.
The resulting blocks of knee joint specimens were sectioned in the frontal plane at a thickness of 5 lm with a Jung Model K microtome (Reichert-Jung, Nussloch, Germany). For histomorphometric analysis, the following items were measured in the secondary spongiosa extending 1.3-3.9 mm distally from the proximal growth cartilage of the tibia: bone volume/tissue volume (BV/TV), expressed as a percentage [18] ; osteoid volume/tissue volume (OV/ TV), expressed as a percentage [18] ; osteoblast surface/ bone surface (Ob.S/BS), expressed as a percentage [18] ; osteoid surface/bone surface (OS/BS), expressed as a percentage [18] ; trabecular thickness (Tb.Th), in micrometers [18] ; trabecular number (Tb.N), per millimeter [18] ; trabecular separation (Tb.Sp), in micrometers [18] ; osteoclast surface/bone surface (Oc.S/BS), expressed as a percentage [18] ; eroded surface/bone surface (ES/BS), expressed as a percentage [18] ; osteoclast number/bone surface (N.Oc/ BS), per millimeter [18] ; mineralizing surface/bone surface (MS/BS), expressed as a percentage [18] ; mineral apposition rate (MAR), in micrometers per day [18] ; and bone formation rate/bone volume (BFR/BV), expressed as a percentage per year [18] . Each parameter was expressed according to the classification of Parfitt et al. [18] .
Bone histomorphometric analysis was performed using semiautomatic image analysis software (System Supply, Nagano, Japan) and an optical fluorescent microscope (BX 51; Olympus, Tokyo, Japan). These parameters were measured by an investigator blinded to the experimental groups.
Histological Evaluation of Arthritis
Arthritis was evaluated histologically by preparing nondecalcified specimens from the knee joints used in bone histomorphometry. The following parameters were measured in the medial half area of the medial compartment using a microscope with a magnifying power of 4 9 10: total tissue area (in millimeters squared), articular cartilage area (in millimeters squared), and synovial tissue area (in millimeters squared). The entire area was obtained by tracing the tissue perimeter or the borders of the area. Articular cartilage area was measured at the tibial and femoral side. Synovial tissue area included the total tissue area of the synovium, infiltrating inflammatory cells, and proliferating fibroblasts as well as the inflammatory granulation tissue pannus with scar-like fibrous tissue (including the eroded areas of the bone). Each parameter was measured using a semiautomatic digitizer connected to a personal computer (System Supply). CVs for this analysis were 2% for total tissue area, 11.1% for synovial tissue area, and 10.8% for articular cartilage area.
Biochemical Assays of Serum
Blood was collected by cardiac puncture at death. Serum was isolated by centrifugation and stored at -70°C. Serum interleukin-6 (IL-6) was measured by enzyme-linked immunosorbent assay (ELISA) targeted against rat IL-6 (Invitrogen, Camarillo, CA).
Statistical Analysis
Changes of body weight and hind paw thickness were analyzed by two-way repeated analysis of variance (ANOVA) for the effects of RAL administration and OVX and their interactions. The data for BMD, bone histomorphometry, histological evaluation, and biochemical assays of serum were compared by two-way factorial ANOVA. Fisher's protected least significant difference (PLSD) procedure was performed after ANOVA. The incidence of arthritis was compared among the four collagen-sensitized groups using the chi-squared test. For comparison of the arthritis score and radiographic score, the Kruskal-Wallis test was performed among the four collagen-sensitized groups. Scheffe's test was performed after the Kruskal-Wallis test. Data from rats that developed arthritis were used for body weight, arthritis score, hind paw thickness, radiographic score, BMD, bone histomorphometry, histologic evaluation, and serum cytokine levels. Twelve rats that did not develop arthritis (three in the CIA ? OVX ? RAL group, four in the CIA ? sham ? RAL group, five in the CIA ? sham ? Veh group) and one that died under anesthesia (in the CIA ? OVX ? RAL) were excluded from the analysis. Statistical analysis was performed using StatView software (version 5.0; SAS Institute, Cary, NC); P \ 0.05 was considered statistically significant.
Results
Changes in Body Weight
At 0, 2, and 4 weeks after sensitization, mean values for body weight were measured (Table 1) .Arthritis-induced rats showed significant reduction in body weight compared with CNT at 4 weeks (Fisher's PLSD test, P \ 0.01).
Changes in Arthritis
At 2, 3, and 4 weeks after sensitization, the incidence of arthritis was demonstrated (Table 2 ), but there was no statistically significant difference between the four CIAinduced groups (chi-squared test, P [ 0.05). In the four experimental groups with CIA, joint swelling started to occur 2 weeks after sensitization and developed rapidly until 4 weeks. RAL administration suppressed hind paw thickness significantly (two-way ANOVA, P \ 0.001), and there were significant differences between the CIA ? OVX ? RAL group and the other CIA-induced groups at 3 and 4 weeks (Fisher's PLSD test, P \ 0.05) (Fig. 1) . There was no significant effect of OVX on hind paw thickness, nor was there an interaction between OVX and RAL. The arthritis score increased rapidly from 2 weeks to 4 weeks, and there were significant differences at 3 and 4 weeks between the four collagen-sensitized groups (KruskalWallis test, P \ 0.05) ( Table 2) . At 3 weeks, the score in the CIA ? OVX ? RAL group was significantly lower than that in the CIA ? sham ? Veh group (Scheffe's test, P \ 0.05).
Findings of Radiographic Examination
Joint destruction was observed in all collagen-sensitized groups. There was a significant difference between the four experimental groups (Kruskal-Wallis test, P \ 0.05). The score in the CIA ? OVX ? RAL group was significantly lower than that in the CIA ? sham ? Veh group (Scheffe's test, P \ 0.05) ( Table 2 ).
BMD and Cortical Bone Thickness
Distal Metaphysis of the Femur
Total bone density and cortical thickness were significantly higher in the RAL groups (two-way ANOVA, P \ 0.01), and there were significant differences between the CIA ? sham ? RAL and CIA ? sham ? Veh groups as well as between the CIA ? sham ? RAL and CIA ? OVX ? Veh groups (Fisher's PLSD test, P \ 0.05) ( Table 3 ). There was no significant effect of OVX, nor was there an interaction between OVX and RAL.
Diaphysis of the Femur
Trabecular bone density, cortical bone density, and cortical thickness were significantly higher in the RAL groups (two-way ANOVA, P \ 0.05); and there were significant differences among the five groups (Table 3 ). There was no significant effect of OVX, nor was there an interaction between OVX and RAL.
Bone Histomorphometry BV/TV was higher in the RAL groups than in the Veh groups; the effect of RAL was significant (two-way ANOVA, P \ 0.05). ES/BS, Oc.S/BS, and N.Oc/BS were lower in the RAL groups; and there was a significant RAL effect (two-way ANOVA, P \ 0.0001). On the other hand, OVX increased ES/BS, Oc.S/BS, and Oc.N/BS significantly (two-way ANOVA, P \ 0.01). There were significant differences among the five groups (Table 4) . There was no significant interaction between RAL administration and OVX. There was no significant difference between groups with respect to MS, MAR, or BFR.
Histological Evaluation of Arthritis
The CIA groups exhibited proliferating joint synovium and eroding joint cartilage. RAL administration had a significant effect on inhibition of synovial proliferation (two-way ANOVA, P \ 0.05), and there were significant differences among the five groups (Fig. 2) . The articular cartilage area/ total tissue area in the RAL groups was not significantly higher than in the Veh groups (two-way ANOVA, P [ 0.05). OVX had no effect on proliferating joint synovium or eroding joint cartilage. There was no significant interaction between RAL administration and OVX.
Biochemical Assays of the Serum
The mean IL-6 values are shown in Table 4 . No significant effect of RAL was observed.
Discussion
The CIA rat is an established model for studying the pathology and treatment of RA [12, 19] . In this study, we evaluated the effects of RAL on CIA rats and demonstrated that RAL reduced hind paw thickness, arthritis score, and radiographic score. Histologic evaluation revealed that intraarticular synovial proliferation was also inhibited by RAL. Bone loss, especially osteoclastic bone resorption, was also reduced by RAL. However, the interaction between RAL and OVX had no effect on arthritis or bone loss. OVX increases the incidence of arthritis and accelerates inflammation caused by collagen type II immunization; estrogen replacement inhibits these arthritic symptoms [20, 21] . The anti-inflammatory mechanism of estrogen is unclear, but it seems that estrogen directly or indirectly regulates the immune system. Estrogen deficiency increases expression of CD16 in monocytes; inflammatory cytokines such as IL-6 and TNF-a are increased upon stimulation of CD16 [22] . Therefore, estrogen can affect immune-mediated effects on arthritis. The mechanism by which RAL inhibits inflammation remains unknown. It is reported that RAL significantly lowers the levels of mRNA expression of both RANKL and TNF-a, which represent important mediators of inflammation and bone destruction at the beginning of the arthritis in CIA mice [9] . RAL decreases cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS), which are involved in regulating the production of proinflammatory cytokine, and increases expression of cytoprotective heat shock protein 72 in CIA rats; this marker is closely associated with remission of the inflammatory reaction [10] . It has also been reported that serum levels of IL-6 are decreased by RAL in CIA mice [11] . In this study, the mean IL-6 value was lower in the RAL groups, but the differences were not statistically significant. Recently, functional estrogen receptors (ER-a) have been detected in synoviocytes [23] . RAL inhibited urokinase-type plasminogen activator (u-PA)-dependent proliferation of RA synoviocytes in an in vitro study [24] . In this study, intraarticular synovium proliferation was reduced by RAL, despite the fact that serum IL-6 was not lowered. Therefore, RAL potentially affects ERs of synoviocytes directly and thereby inhibits their proliferation. The differences between the anti-inflammatory mechanisms of estrogen and RAL are unclear. However, it seems that estrogen is more effective against arthritis than RAL [9, 10] ; RAL lacks the suppressive effects of estrogen on T cell-mediated and granulocyte-dependent inflammation in mice [25] . At the tissue level, it has also been reported that estrogen and RAL restore the downregulation of tendon collagen turnover and tendon elasticity in cultures of rat tendon fibroblasts [26] . Levormeloxifene has been reported to suppress cartilage degradation in OVX rodents and postmenopausal women [27] .
Since all of the RAL effects were not modulated by OVX in this study, RAL seemed to reduce arthritis despite the status of estrogen. This was observed in a previous estrogen study [5] , which demonstrated that estrogen could suppress arthritis in estrogen-replete rats. These findings indicate that the development and severity of arthritis in CIA rats are ameliorated by RAL as well as estrogen, even in the estrogen-replete state. Jansson and Holmdahl [28] demonstrated that estrogen decreases the rate of arthritis in OVX as well as intact CIA mice. They also showed that estrogen treatment lowers the incidence of arthritis in noncastrated and castrated males, thus showing that the antiarthritic effect of estrogen is not dependent on gender. An anti-inflammatory acute effect of administration of estrogen or SERM was observed in carrageenan-induced acute inflammation in normal male rats [10] . Our finding that RAL decreased the severity of arthritis in non-OVX CIA rats is consistent with these observations.
Total bone density and cortical thickness of the distal metaphysis of the femur under RAL were higher than Veh. As in the metaphysis, trabecular bone density, cortical bone density, and cortical thickness in the RAL administration groups were higher than in the Veh groups. These findings indicate that the bone loss is suppressed by RAL in CIA rats even in the estrogen-replete state. Histomorphometric analysis revealed that parameters of bone resorption (e.g., Oc.S, ES/BS, and N.Oc) in the RAL groups were lower than in the Veh groups. RAL had no effect on bone-formation parameters. RAL plays a role similar to that of estrogen in the inhibition of osteoclastic bone resorption in postmenopausal women or estrogen-depleted animals [29] [30] [31] [32] , although no data are available regarding the estrogenreplete state. This study demonstrated that RAL inhibited osteoclastic bone resorption even in estrogen-replete animals with CIA, which was consistent with our observation in the previous estrogen study [5] . It has been reported that there is no significant difference in estradiol or progesterone between RA patients and controls; however, pituitary ovary secretory function is disturbed in premenopausal and postmenopausal RA women [33] . We speculate that CIA might substantially reduce the estrogen status in non-OVX rats. Further experiments will be necessary in order to clarify the mechanisms of osteoclast inhibition in the estrogen-replete state.
This study has several limitations. First, we did not observe the effect of OVX on arthritis or bone density that was reported previously [13] . Our previous studies demonstrated that arthritis in CIA rats reaches a peak 4 weeks after initial sensitization [12] [13] [14] ; therefore, we terminated the study at 4 weeks in order to investigate the effect of RAL on arthritis. Thus, the duration of observation might not have been long enough for OVX effects on bone loss to Fig. 2 Histologic evaluation of arthritis. Data represent the mean ± SEM. RAL administration significantly inhibited intra-articular synovium proliferation (RAL P \ 0.05, by two-way ANOVA). Eroding joint cartilage was inhibited by RAL but not significantly. OVX did not influence synovium proliferation and eroding joint cartilage. There was no significant interaction between RAL administration and OVX. Post-hoc comparisons performed among the five groups by Fischer's PLSD test.
* P \ 0.05 (vs.CNT), # P \ 0.05 (vs. CIA ? OVX ? RAL) become obvious at the time of death (4 weeks) since the influence of OVX on CIA is most obvious from 6 to 8 weeks after sensitization [13] . Second, only data from rats that developed arthritis were used for BMD measurements, histomorphometry, and IL-6 measurements; however, only six or seven animals were analyzed in the CIA ? sham groups, and this might reduce our power of detection. Third, this study lacks molecular analysis. A more detailed analysis, of the cellular composition of the tissue and/or expression of inflammatory and bone-regulating cytokines and factors, might be helpful in elucidating the mechanism of the observed effects of RAL.
In conclusion, this study demonstrated that RAL could suppress arthritis and bone loss in estrogen-replete or -depleted rats. These findings, using an animal model, indicate the potential usefulness of RAL as an effective treatment for premenopausal RA patients as well as postmenopausal ones.
